Please assess the completion status of the following clinical trial:

Trial Title: Effects of dapaglifloziN Therapy on Myocardial Perfusion Reserve in Prediabetic Patients With Stable coronarY Artery Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Men or women at least 18 years of age~2. Prediabetes by ADA criteria (fasting glucose 100-125mg/dl, or HbA1C 5.7-6.4%)~3. Stable coronary artery disease~4. Global myocardial perfusion reserve (MPR) index \< 2.0~5. The patient or guardian agrees to the study protocol and the schedule of clinical and dynamic SPECT follow-up, and provides informed, written consent, as approved by the appropriate Institutional Review Board/Ethical Committee of the respective clinical site.~Exclusion Criteria:~1. Contraindications to dapagliflozin~2. Significant renal disease manifested by eGFR\<30 ml/min/1.73m²~3. Unstable or rapidly progressing renal disease~4. Acute coronary syndrome, or any other major cardiovascular events within the previous 6 months~5. Stent placement, or coronary artery bypass graft surgery within the previous 6 months~6. Planned revascularization within 6 months~7. Significant disease (diameter stenosis \>70% by coronary CT angiography) in major epicardial coronary arteries~8. Heart failure requiring loop diuretics~9. Hepatic disease or biliary tract obstruction, or significant hepatic enzyme elevation (ALT or AST \> 3 times upper limit of normal).~10. Contraindication to adenosine stress test~11. Current treatment for the active cancer~12. Women of child bearing potential who are not willing to use a medically accepted method of contraception. Patient's pregnancy confirmed by positive pregnancy test, or breast-feeding.~13. Expected life expectancy \< 1 year~14. Any clinically significant abnormality identified at the screening visit, physical examination, laboratory tests which, in the judgment of the investigator, would preclude safe completion of the study.~15. Unwillingness or inability to comply with the procedures described in this protocol.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dapagliflozin (Type: EXPERIMENTAL): None
- Lifestyle modification (Type: OTHER): None

Based on this trial design, predict the completion outcome and termination type (if applicable).